Synergy Cancer Research Results

Synergy, Synergy: Click to Expand ⟱
Source:
Type:

Synergy — Interaction in which two or more agents, treatments, or biological interventions produce a combined effect greater than would be expected from their individual effects. In pharmacology and cancer research, synergy commonly refers to enhanced therapeutic efficacy when a compound is combined with chemotherapy, radiation, targeted therapy, or another bioactive agent.

Typical modulation in cancer: ↑ synergy is generally favorable when it increases tumor-cell killing, suppresses proliferation, enhances apoptosis or ferroptosis, or improves sensitivity to anticancer therapy. Synergy should be distinguished from simple additive effects and ideally supported by quantitative combination analysis such as combination index, Bliss independence, Loewe additivity, or related methods.

Typical modulation in Alzheimer’s disease: Context-dependent. Synergy may describe enhanced neuroprotective, anti-inflammatory, antioxidant, or cognitive effects produced by combinations of compounds or treatments, but it is not a disease-specific molecular pathway.
Scientific Papers found: Click to Expand⟱
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, *antiOx↑, *neuroP↑, *BioAv↑, *Half-Life↝, *toxicity↓, *PGE2↓, *TNF-α↓, *IL1β↓, *NO↓, *NF-kB↓, *PPARγ↓, COX2/PTGS2↓, *ROS↓, *SOD↑, *Catalase↑, *TAC↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *NADPH↑, *GPx↑, *AntiBio↑, *eff↑, *AntiFungal↑, *AntiViral↑, *TRPA1↑, Synergy↑, TumCCA↑, ROS↑, MAPK↝, mTOR↝, Apoptosis↑, survivin↓, Akt↓, p38↑, cl‑PARP↑, cl‑Casp3⇅, P53↑, BAX↑, Cyt‑c↑, Casp9↑, Dose↝, *Aβ↓, *tau↓, *GSK‐3β↓, *BACE/β-secretase↓, *cardioP↑, MFN2↑,
6462- 1,8-Cin,    Modes of Action of 1,8-Cineol in Infections and Inflammation
- Review, Var, NA - Review, AD, NA
*BioAv↑, *BBB↑, *AntiViral↑, *Bacteria↓, *AntiFungal↑, *Inflam↓, *BioAv↑, *MUC2↓, *MUC19↓, *NF-kB↓, *ICAM-1↓, *VCAM-1↓, DNAdam↑, *lipid-P↓, *PGE2↓, *IL4↓, *IL6↓, *IL1β↓, *IL6↓, Synergy↑, TGF-β↓, fascin↓, VEGF↓, MMP9↓, *MAPK↓, *ERK↓, JNK↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↑, *neuroP↑, *GSK‐3β↓, *AGEs↓, *BBB↑, *NLRP3↓,
2325- 2DG,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
HK2↓, Glycolysis↓, PKM2↓, LDHA↓, TumCD↑, ChemoSen↑, Synergy↑,
1340- 3BP,    Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study
- Review, NA, NA
Glycolysis↓, HK2↓, LDH↓, OXPHOS↓, angioG↓, H2O2↑, Synergy↑,
1341- 3BP,    The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate
- Review, NA, NA
Glycolysis↓, OXPHOS↓, *toxicity↓, ROS↑, GSH↓, Synergy↑,
5272- 3BP,    The efficacy of the anticancer 3-bromopyruvate is potentiated by antimycin and menadione by unbalancing mitochondrial ROS production and disposal in U118 glioblastoma cells
- in-vitro, GBM, U87MG - in-vitro, Nor, HEK293
Glycolysis↓, ROS↑, GPx↓, eff↓, OXPHOS↓, HK2↓, ATP↓, ROS↑, ER Stress↑, BioAv↓, Cyt‑c↑, Synergy↑,
326- AgNPs,  TSA,    Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles
- in-vitro, Cerv, HeLa
Apoptosis↑, ChrMod↝, Synergy↑,
356- AgNPs,  MF,    Anticancer and antibacterial potentials induced post short-term exposure to electromagnetic field and silver nanoparticles and related pathological and genetic alterations: in vitro study
- in-vitro, BC, MCF7 - in-vitro, Bladder, HTB-22
Apoptosis↑, P53↑, iNOS↑, NF-kB↑, Bcl-2↓, ROS↑, SOD↑, TumCCA↑, Synergy↑, Catalase↑, other↑,
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2/PTGS2↓, *IL6↓, *TNF-α↓, *MPO↓, *Synergy↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2/KDR/Flk1↓, p‑FAK↓,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, Synergy↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
1158- And,  GEM,    Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1/CCND1↓, cycE/CCNE↓, survivin↓, XIAP↓, Bcl-2↓, Synergy↑,
1348- And,    Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
- in-vitro, BC, MCF7 - in-vitro, BC, T47D - in-vivo, NA, NA
ERα/ESR1↓, TumCG↓, ROS↑, FOXM1↓, Synergy↑,
2635- Api,  CUR,    Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
- in-vitro, Cerv, HeLa
TumCD↑, Synergy↑, TumAuto↑, ER Stress↑, Paraptosis↑, GRP78/BiP↓, Dose↝,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, Synergy↑, AntiAg↑, Synergy↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2/BIRC3↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, Synergy↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, Synergy↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2/PTGS2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, ChemoSen↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, Synergy↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
2574- ART/DHA,    Artemisinin: A Promising Adjunct for Cancer Therapy
- Review, Var, NA
selectivity↑, Synergy↑,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
Synergy↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, Synergy↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
Synergy↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, Synergy↑, ChemoSen↑, ChemoSen↑, Synergy↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
Synergy↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,
1525- Ba,  almon,    Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway
- in-vitro, Lung, H1975 - in-vivo, Lung, NA
Synergy↑, TumCP↓, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, cl‑Casp9↑, p‑PI3K↓, p‑Akt↓, ROS↑, eff↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, Synergy↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2/PTGS2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1394- BBR,  DL,    Synergistic Inhibitory Effect of Berberine and d-Limonene on Human Gastric Carcinoma Cell Line MGC803
- in-vitro, GC, MGC803
Synergy↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, TumCCA↑,
2702- BBR,    The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
- in-vitro, Lung, A549 - in-vitro, Lung, H1975
TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1 / PDPK1↓, DNMT1↓, Synergy↑,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1/CCL2↓, COX2/PTGS2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, Synergy↑, EGFR↓, Glycolysis↓, Dose?, p27/CDKN1B↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2/KDR/Flk1↓, ChemoSen↑, Synergy↑, Synergy↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
2729- BetA,    Betulinic acid in the treatment of tumour diseases: Application and research progress
- Review, Var, NA
ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, Synergy↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP/DDIT3↑, *toxicity↓,
2737- BetA,    Multiple molecular targets in breast cancer therapy by betulinic acid
- Review, Var, NA
TumCP↓, Cyc↓, TOP1↓, TumCCA↑, angioG↓, NF-kB↓, Sp1/3/4↓, VEGF↓, MMPs↓, ChemoSen↑, eff↑, MMP↓, ROS↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, lipid-P↑, RadioS↑, Synergy↑,
696- Bor,    Nothing Boring About Boron
- Review, Var, NA
*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *Synergy↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑, *chemoPv↑,
2767- Bos,    The potential role of boswellic acids in cancer prevention and treatment
- Review, Var, NA
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1/CCL2↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2/PTGS2↓, MMP9↓, CXCR4↓, VEGF↓, Synergy↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, Synergy↑, MMP1↓, MMP2↓, Synergy↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
1651- CA,  PBG,    Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer
- Review, Var, NA
Apoptosis↑, TumCCA↓, TumCMig↓, TumMeta↓, ChemoSen↑, eff↑, Synergy↑, eff↓, eff↝, Dose∅, AMPK↑, p62↓, LC3II↑, Ca+2↑, Bax:Bcl2↑, CDK4↑, CDK6↑, RB1↑, EMT↓, E-cadherin↑, Vim↓, β-catenin/ZEB1↓, NF-kB↓, angioG↑, VEGF↓, TSP-1↑, MMP9↓, MMP2↓, ChemoSen↑, Synergy↑, ROS↑, CSCs↓, Fas↑, P53↑, BAX↑, Casp↑, β-catenin/ZEB1↓, NDRG1↑, STAT3↓, MAPK↑, ERK↑, Synergy↑, Synergy↑, Synergy↑,
2018- CAP,  MF,    Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma
- Review, HCC, NA
TRPV1↑, eff↑, Akt↓, mTOR↓, p‑STAT3↑, MMP2↑, ER Stress↑, Ca+2↑, ROS↑, selectivity↑, MMP↓, Synergy↑,
2803- CHr,  5-FU,    Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells
- in-vitro, GC, AGS
ChemoSen↑, TumCCA↑, Synergy↑, MDR1↓,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, Synergy↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2/PTGS2↓, NF-kB↓, PDK1 / PDPK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, Synergy↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, Synergy↑, Synergy↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, Synergy↑,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C/p57↑, p‑STAT3↑, MMP2↓, MMP9↓, Synergy↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2/PTGS2↓, Synergy↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2/PTGS2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, Synergy↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, Synergy↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2/PTGS2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1 / PDPK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
2789- CHr,    Anticancer Activity of Ether Derivatives of Chrysin
- Review, Var, NA
eff↑, COX2/PTGS2↓, PGE2↓, Synergy↑,
2790- CHr,    Chrysin: Pharmacological and therapeutic properties
- Review, Var, NA
*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, Synergy↑, hTERT/TERT↓, cycD1/CCND1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, Synergy↑, Ca+2↑,
1576- Citrate,    Targeting citrate as a novel therapeutic strategy in cancer treatment
- Review, Var, NA
TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, Synergy↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, ChemoSen↑, eff↑, eff↑, eff↑,
1572- Cu,    Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy
- Review, NA, NA
eff↑, Fenton↑, ROS↑, eff↑, mtDam↑, BAX↑, Bcl-2↓, MMP↓, Cyt‑c↑, Casp3↑, ER Stress↑, CHOP/DDIT3↑, Apoptosis↑, selectivity↑, Synergy↑, Pyro↑, Paraptosis↑, Cupro↑, ChemoSen↑, eff↑,
1609- CUR,  EA,    Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells
- in-vitro, Cerv, NA
Synergy↑, Dose∅, ROS↑, DNAdam↑, P53↑, P21↑, BAX↑, Dose∅,
1978- CUR,    Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells
- in-vitro, Cerv, HeLa
TrxR1↓, ROS↑, DNA-PK↑, Synergy↑, Trx↓, Trx1↓,
129- CUR,    Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation
- vitro+vivo, Pca, LNCaP
JNK↓, H3K4↓, TumCG↓, Apoptosis↑, Synergy↑,
130- CUR,    Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
BAD↝, BAX↝, Synergy↑,
12- CUR,    Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells
- in-vitro, MB, DAOY
HH↓, Shh↓, Gli1↓, PTCH1↓, cMyc↓, n-MYC↓, cycD1/CCND1↓, Bcl-2↓, NF-kB↓, Akt↓, β-catenin/ZEB1↓, survivin↓, Apoptosis↑, ChemoSen↑, RadioS↑, Synergy↑,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, Synergy↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1/CCND1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
1878- DCA,  5-FU,    Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer
- in-vitro, CRC, LS174T - in-vitro, CRC, LoVo - in-vitro, CRC, SW-620 - in-vitro, CRC, HT-29
tumCV↓, Synergy↑, PDKs↓, lactateProd↓, Glycolysis↓, mitResp↑, TumCCA↑, Bcl-2↓, BAX↑, Casp3↑,

Showing Research Papers: 1 to 50 of 156
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 156

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↓, 1,   Catalase↑, 2,   CYP1A1↑, 1,   Fenton↑, 3,   Ferroptosis↑, 2,   frataxin↑, 1,   GPx↓, 1,   GPx↑, 2,   GSH↓, 8,   GSH↑, 1,   GSSG↑, 1,   GSTP1/GSTπ↓, 2,   GSTs↓, 1,   H2O2↑, 3,   HO-1↓, 3,   HO-1↑, 5,   hyperG↓, 1,   Keap1↑, 1,   lipid-P?, 1,   lipid-P↓, 1,   lipid-P↑, 4,   MDA↓, 1,   MFN2↑, 1,   NQO1↑, 1,   NRF2↓, 9,   NRF2↑, 8,   OXPHOS↓, 4,   OXPHOS↑, 1,   OXPHOS↝, 1,   PrxI↓, 1,   PYCR1↓, 1,   ROS?, 2,   ROS↓, 8,   ROS↑, 97,   ROS⇅, 1,   i-ROS↑, 1,   mt-ROS↑, 1,   SIRT3↓, 1,   SIRT3↑, 1,   SOD↓, 1,   SOD↑, 3,   Trx↓, 2,   Trx1↓, 1,   TrxR↓, 2,   TrxR1?, 1,   TrxR1↓, 1,   xCT/SLC7A11↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

KLF5↓, 1,   Tf↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↑, 1,   AIF↑, 1,   ATP↓, 8,   ATP↑, 1,   mt-ATP↓, 1,   BCR-ABL↓, 1,   CDC2↓, 1,   CDC25↓, 1,   EGF↓, 2,   FGFR1↓, 1,   Insulin↓, 1,   MEK↓, 4,   mitResp↑, 3,   MMP↓, 32,   MMP↑, 1,   Mortalin↓, 1,   mtDam↑, 5,   OCR↓, 1,   OCR↑, 1,   Raf↓, 2,   c-Raf↓, 1,   SDH↓, 1,   XIAP↓, 8,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 2,   ACLY↓, 2,   p‑ACLY↓, 1,   adiP↑, 1,   ALAT↓, 1,   AMPK↑, 9,   ATG7↑, 2,   CAIX/CA9↓, 1,   CAIX/CA9↑, 1,   citrate↓, 1,   cMyc↓, 10,   CPT1A↓, 1,   CYP3A4↓, 1,   FASN↓, 2,   FASN↑, 1,   GlucoseCon↓, 3,   GlucoseCon↑, 1,   GlutMet↓, 1,   glyC↓, 1,   Glycolysis↓, 19,   Glycolysis↑, 1,   HK2↓, 11,   HMG-CoA↓, 1,   KeyT↑, 1,   lactateProd↓, 5,   lactateProd↑, 1,   LDH↓, 6,   LDHA↓, 1,   LDL↓, 1,   NADPH↓, 3,   NADPH↑, 1,   PDH↓, 1,   PDH↑, 3,   p‑PDH↑, 1,   PDHB↓, 1,   PDK1 / PDPK1↓, 5,   PDK3↑, 1,   PDKs↓, 8,   PFK↓, 2,   PFK2?, 1,   PI3K/Akt↓, 1,   PKM2↓, 8,   POLD1↓, 1,   PPARα↓, 2,   PPARγ↑, 1,   p‑S6K↓, 1,   SIRT1↓, 1,   SIRT1↑, 3,   SIRT2↓, 1,   TCA↓, 1,   TS↓, 1,   Warburg↓, 4,   β-oxidation↓, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 38,   ASK1↑, 1,   BAD↑, 3,   BAD↝, 1,   Bak↑, 2,   BAX↓, 2,   BAX↑, 29,   BAX↝, 1,   Bax:Bcl2↑, 9,   Bcl-2↓, 33,   Bcl-xL↓, 6,   BID↑, 1,   BIM↑, 5,   Casp↑, 10,   Casp12?, 1,   Casp12↑, 1,   Casp2↑, 1,   Casp3↓, 1,   Casp3↑, 35,   cl‑Casp3↑, 5,   cl‑Casp3⇅, 1,   pro‑Casp3↑, 1,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 5,   cl‑Casp8↑, 2,   Casp9↑, 18,   cl‑Casp9↑, 3,   CK2↓, 4,   Cupro↑, 1,   Cyt‑c↑, 20,   Diablo↑, 3,   DR4↑, 2,   DR5↑, 7,   Fas↑, 4,   FasL↑, 1,   Ferroptosis↑, 2,   GSDME-N↑, 1,   hTERT/TERT↓, 8,   IAP1↓, 1,   cl‑IAP2/BIRC3↑, 1,   iNOS↓, 3,   iNOS↑, 2,   JNK↓, 2,   JNK↑, 5,   p‑JNK↓, 2,   MAPK↓, 5,   MAPK↑, 3,   MAPK↝, 1,   Mcl-1↓, 7,   Mcl-1↑, 1,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Myc↓, 1,   Necroptosis↑, 2,   necrosis↑, 1,   NOXA↑, 1,   p27/CDKN1B↑, 5,   p38↓, 1,   p38↑, 3,   Paraptosis↑, 2,   Proteasome↓, 1,   PUMA↑, 1,   Pyro↑, 2,   survivin↓, 10,   Telomerase↓, 6,   TRAIL↑, 1,   TRPV1↑, 1,   TumCD↑, 6,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 29,   Akt↑, 5,   p‑Akt↓, 5,   EF-1α↓, 1,   FOXD3↑, 1,   HER2/EBBR2↓, 3,   p70S6↓, 1,   SOX9?, 1,   Sp1/3/4↓, 7,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ChrMod↝, 1,   cJun↓, 4,   cJun↑, 2,   EZH2↓, 1,   H3↑, 1,   ac‑H3↑, 1,   H3K4↓, 1,   H4↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-21↓, 1,   miR-27a-3p↓, 1,   other↓, 2,   other↑, 3,   other↝, 1,   p‑pRB↓, 1,   tumCV↓, 11,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 5,   cl‑CHOP/DDIT3↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 17,   GRP78/BiP↓, 1,   GRP78/BiP↑, 5,   GRP78/BiP↝, 1,   HSP27↓, 2,   HSP70/HSPA5↓, 4,   HSP70/HSPA5↑, 1,   HSP72↑, 1,   HSP90↓, 2,   HSPs↓, 1,   IRE1↑, 3,   PERK↑, 3,   UPR↑, 4,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↓, 1,   Beclin-1/ATG6↑, 4,   BNIP3↑, 1,   LAMP2↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3B↑, 1,   LC3II↓, 1,   LC3II↑, 6,   p62↓, 4,   p62↑, 5,   SESN2↑, 1,   TumAuto↑, 11,   TumAuto⇅, 1,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   DNA-PK↑, 2,   DNAdam↑, 18,   DNArepair↑, 1,   DNMT1↓, 5,   DNMT3A↓, 1,   DNMTs↓, 2,   m-FAM72A↓, 1,   GADD45A↑, 1,   MGMT↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 16,   p‑P53↑, 2,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 16,   PCNA↓, 6,   SIRT6↓, 1,   TP53↓, 1,   TP53↑, 2,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 11,   CDK4↓, 16,   CDK4↑, 3,   Cyc↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 21,   cycE/CCNE↓, 6,   cycE1↓, 1,   P21?, 2,   P21↓, 1,   P21↑, 13,   RB1↑, 1,   p‑RB1↓, 2,   Securin↓, 1,   TumCCA?, 1,   TumCCA↓, 3,   TumCCA↑, 35,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD133↓, 2,   CD44↓, 2,   cFos↓, 4,   cMYB↓, 2,   CSCs↓, 10,   Diff↓, 1,   EMT↓, 23,   ERK↓, 8,   ERK↑, 4,   p‑ERK↓, 4,   FOXM1↓, 1,   FOXO3↓, 1,   FOXO3↑, 3,   FOXO4↓, 1,   FOXO4↑, 1,   Gli↓, 1,   Gli1↓, 3,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 2,   p‑GSK‐3β↑, 1,   HDAC↓, 10,   HDAC1↓, 1,   HDAC2↓, 2,   HDAC3↓, 1,   HDAC8↓, 1,   HH↓, 4,   HMTs↓, 1,   IGF-1↓, 6,   IGF-1R↓, 2,   IGFBP1↑, 1,   IGFBP3↑, 1,   KLF4↓, 1,   Let-7↑, 2,   miR-34a↑, 1,   mTOR↓, 16,   mTOR↑, 2,   mTOR↝, 1,   p‑mTOR↓, 1,   mTORC1↓, 3,   p‑mTORC1↓, 1,   mTORC2↓, 1,   n-MYC↓, 2,   Nanog↓, 6,   Nestin↓, 3,   NOTCH↓, 1,   NOTCH↑, 1,   NOTCH1↓, 3,   NOTCH1↑, 3,   NOTCH3↓, 1,   OCT4↓, 5,   P70S6K↓, 1,   p‑P70S6K↓, 1,   P90RSK↓, 1,   PI3K↓, 18,   PI3K↑, 3,   p‑PI3K↓, 1,   PTCH1↓, 2,   PTCH2↓, 1,   PTEN↑, 6,   RAS↓, 2,   Shh↓, 3,   SHP1↑, 1,   Smo↓, 1,   SOX2↓, 3,   STAT3↓, 16,   p‑STAT3↓, 3,   p‑STAT3↑, 2,   STAT5↓, 1,   STAT6↓, 1,   TCF↓, 1,   TCF↑, 1,   TCF-4↓, 1,   TOP1↓, 4,   TOP2↓, 1,   TOP2↑, 1,   TumCG↓, 24,   TumCG↑, 2,   Wnt↓, 8,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

annexin II↓, 1,   AntiAg↑, 1,   AP-1↓, 2,   Ca+2↓, 1,   Ca+2↑, 8,   cal2↑, 1,   CDKN1C/p57↑, 1,   CLDN1↓, 2,   CLDN2↑, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 14,   ER-α36↓, 1,   FAK↓, 3,   p‑FAK↓, 2,   fascin↓, 1,   Fibronectin↓, 4,   GLI2↓, 1,   ITGB1↓, 1,   ITGB3↓, 1,   ITGB4↓, 1,   Ki-67↓, 5,   Ki-67↑, 1,   KLF2↓, 1,   L-sel↑, 1,   LAMs↓, 1,   MALAT1↓, 2,   MET↓, 1,   miR-200b↑, 1,   MMP-10↓, 1,   MMP1↓, 3,   MMP13↓, 1,   MMP2↓, 20,   MMP2↑, 1,   MMP3↓, 1,   MMP7↓, 4,   MMP9↓, 21,   MMP9↑, 1,   MMPs↓, 9,   MUC1↑, 1,   MUC4↓, 1,   N-cadherin↓, 4,   PAK1↓, 1,   PDGF↓, 1,   PKA↓, 1,   RECK↑, 1,   Rho↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   ROCK1↓, 2,   Slug↓, 4,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 7,   SOX4↓, 1,   STAC2↓, 1,   TET1↑, 3,   TGF-β↓, 5,   TIMP1↓, 1,   TIMP1↑, 3,   TIMP2↑, 2,   Treg lymp↓, 2,   TSP-1↑, 1,   TumCA↓, 1,   TumCI↓, 15,   TumCMig↓, 14,   TumCMig↑, 1,   TumCP↓, 18,   TumCP↑, 1,   TumMeta↓, 11,   TumMeta↑, 1,   Twist↓, 4,   uPA↓, 6,   uPAR↓, 1,   Vim?, 1,   Vim↓, 10,   Zeb1↓, 6,   ZO-1↑, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 12,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 23,   angioG↑, 1,   ATF4↓, 1,   ATF4↑, 3,   EGFR↓, 9,   eNOS↓, 2,   eNOS↑, 1,   HIF-1↓, 2,   Hif1a↓, 21,   Hif1a↑, 1,   NO↓, 2,   NO↑, 1,   p‑PDGFR-BB↓, 1,   VEGF↓, 30,   VEGFR2/KDR/Flk1↓, 3,   ZBTB10↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,   CellMemb↑, 1,   GLUT1↓, 2,   GLUT1↑, 1,   GLUT3↑, 1,   P-gp/ABCB1↓, 4,   SMCT1∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCR7↓, 1,   CD4+↑, 1,   COX2/PTGS2↓, 23,   COX2/PTGS2↑, 2,   CRP↓, 1,   CXCR4↓, 4,   FOXP3↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 3,   IL10↓, 3,   IL10↑, 1,   IL1α↓, 1,   IL1β↓, 6,   IL2↑, 3,   IL4↓, 1,   IL4↑, 1,   IL6↓, 11,   IL8↓, 3,   INF-γ↑, 1,   Inflam↓, 5,   IκB↑, 1,   JAK↓, 1,   JAK2↓, 3,   M2 MC↓, 1,   MCP1/CCL2↓, 2,   MIP2↓, 1,   NF-kB↓, 30,   NF-kB↑, 3,   NK cell↑, 2,   p65↓, 4,   PD-1↓, 1,   PD-L1↓, 2,   PGE1↓, 1,   PGE2↓, 9,   PSA↓, 3,   PSA∅, 1,   T-Cell↑, 1,   T-Cell↝, 1,   Th1 response↑, 3,   Th2↑, 1,   TLR4↓, 2,   TNF-α↓, 5,   TNF-α↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,   TIM-3↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 2,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 8,   CDK6↓, 3,   CDK6↑, 3,   COMT↓, 2,   CYP19↓, 1,   ERα/ESR1↓, 1,   GR↑, 1,   RANKL↓, 1,   SXR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 11,   BioAv↑, 15,   BioAv↝, 2,   BioEnh↑, 1,   chemoR↓, 1,   ChemoSen↓, 2,   ChemoSen↑, 60,   ChemoSen⇅, 1,   CYP1A2↓, 1,   CYP2C9↓, 1,   Dose?, 1,   Dose↓, 2,   Dose↑, 3,   Dose↝, 9,   Dose∅, 15,   eff↓, 17,   eff↑, 53,   eff↝, 4,   eff∅, 1,   Half-Life↓, 3,   Half-Life↝, 3,   Half-Life∅, 1,   MDR1↓, 3,   MRP1/ABCC1↓, 1,   P450↓, 1,   RadioS↑, 22,   selectivity?, 1,   selectivity↓, 1,   selectivity↑, 33,   Synergy↑, 182,  

Clinical Biomarkers(tgid=22) ⓘ

AFP?, 1,   ALAT↓, 1,   ALP↓, 1,   AR↓, 8,   ascitic↓, 1,   BG↓, 3,   CRP↓, 1,   EGFR↓, 9,   ERα/ESR1↓, 1,   EZH2↓, 1,   FOXM1↓, 1,   GutMicro↑, 3,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 8,   IL6↓, 11,   Ki-67↓, 5,   Ki-67↑, 1,   LDH↓, 6,   Myc↓, 1,   NOS2↓, 1,   PD-L1↓, 2,   PSA↓, 3,   PSA∅, 1,   TP53↓, 1,   TP53↑, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 13,   AntiCan∅, 1,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 2,   CardioT↓, 1,   chemoP↑, 6,   chemoPv↑, 4,   ChemoSideEff↓, 10,   hepatoP↓, 1,   memory↑, 1,   NDRG1↑, 1,   neuroP↑, 4,   OS↑, 8,   QoL↑, 1,   radioP↑, 2,   RenoP↑, 2,   Risk↓, 10,   Risk↑, 2,   Risk∅, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity↝, 1,   toxicity∅, 4,   TumVol↓, 6,   TumW↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 3,  
Total Targets: 626

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   TRPA1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx?, 1,   antiOx↓, 1,   antiOx↑, 10,   Catalase↑, 7,   Copper↓, 1,   Fenton↓, 1,   GPx↑, 7,   GSH↑, 7,   GSR↑, 1,   GSSG↓, 1,   GSSG∅, 1,   GSTs↑, 3,   H2O2↑, 1,   HDL↑, 1,   HO-1?, 1,   HO-1↑, 5,   Iron↓, 1,   Keap1↓, 3,   lipid-P↓, 6,   MDA↓, 7,   MPO↓, 1,   NRF2↑, 10,   ROS?, 1,   ROS↓, 22,   SAM-e↑, 1,   SOD↑, 12,   TAC↑, 1,   TBARS↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 3,   p‑cMyc↑, 1,   H2S↑, 1,   LDH↓, 2,   lipidLev↓, 1,   NAD↝, 1,   NADPH↑, 1,   PPARγ↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Bax:Bcl2↓, 1,   Casp3↓, 1,   cl‑Casp8↑, 1,   iNOS↓, 4,   JNK↓, 1,   MAPK↓, 4,   MAPK↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↓, 2,  

DNA Damage & Repair(tgid=10) ⓘ

GADD45A↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 2,   ERK↑, 1,   GSK‐3β↓, 2,   mTOR↑, 1,   PI3K↓, 3,   PTEN↑, 1,   RAS↓, 1,   TumCG∅, 1,  

Migration(tgid=13) ⓘ

Ca+2↝, 3,   MMP2↓, 1,   PKCδ?, 1,   PKCδ↓, 1,   serineP↓, 1,   VCAM-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   angioG↑, 1,   eNOS↓, 1,   NO↓, 4,   NO↑, 1,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 5,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   ICAM-1↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL4↓, 1,   IL6↓, 6,   Inflam↓, 18,   MUC2↓, 1,   NF-kB↓, 8,   PGE2↓, 4,   TNF-α↓, 8,   VitD↑, 2,  

Cellular Microenvironment(tgid=17) ⓘ

pH↝, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,   Aβ↓, 1,   BACE/β-secretase↓, 1,   NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

testos↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 8,   BioAv↑, 4,   Dose↑, 2,   Dose↝, 1,   eff↑, 3,   Half-Life↓, 1,   Half-Life↝, 2,   P450↓, 1,   selectivity↑, 2,   Synergy↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3,   AST↓, 4,   BMD↑, 1,   BMPs↑, 1,   BP↓, 1,   Calcium↑, 1,   creat↓, 1,   GutMicro↑, 1,   hs-CRP↓, 1,   IL6↓, 6,   LDH↓, 2,   Mag↑, 1,   MUC19↓, 1,   VitD↑, 2,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 6,   CardioT↓, 1,   chemoP↑, 3,   chemoPv↑, 1,   ChemoSideEff↓, 1,   cognitive↑, 4,   hepatoP↑, 6,   memory↑, 4,   neuroP↓, 1,   neuroP↑, 12,   radioP↑, 1,   RenoP↑, 3,   Risk↓, 1,   toxicity↓, 6,   toxicity↑, 2,   toxicity↝, 1,   toxicity∅, 4,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 2,   AntiViral↑, 2,   Bacteria↓, 1,  
Total Targets: 136

Scientific Paper Hit Count for: Synergy, Synergy
10 Dichloroacetate
9 Sulforaphane (mainly Broccoli)
7 Curcumin
7 Resveratrol
7 Chrysin
7 Vitamin C (Ascorbic Acid)
6 Metformin
6 Chemotherapy
6 Fisetin
5 Apigenin (mainly Parsley)
5 Berberine
5 diet FMD Fasting Mimicking Diet
5 Gambogic Acid
5 Rosmarinic acid
5 Vitamin K2
4 Magnetic Fields
4 Artemisinin
4 Propolis -bee glue
4 Piperlongumine
4 Quercetin
4 VitK3,menadione
3 3-bromopyruvate
3 EGCG (Epigallocatechin Gallate)
3 Melatonin
3 Hyperthermia
3 Thymoquinone
2 1,8-Cineole
2 Silver-NanoParticles
2 Allicin (mainly Garlic)
2 Alpha-Lipoic-Acid
2 Andrographis
2 Gemcitabine (Gemzar)
2 Ashwagandha(Withaferin A)
2 Betulinic acid
2 5-fluorouracil
2 Citric Acid
2 Ellagic acid
2 diet Methionine-Restricted Diet
2 Fenbendazole
2 Hydrogen Gas
2 HydroxyCitric Acid
2 Honokiol
2 Lecithin
2 Lycopene
2 Photodynamic Therapy
2 Selenite (Sodium)
2 Vitamin D3
1 2-DeoxyGlucose
1 Trichostatin A
1 5-Aminolevulinic acid
1 Baicalein
1 almonertinib
1 D-limonene
1 Boron
1 Boswellia (frankincense)
1 Caffeic acid
1 Capsaicin
1 Copper and Cu NanoParticles
1 salinomycin
1 Bortezomib
1 diet Ketogenic
1 Oxygen, Hyperbaric
1 Emodin
1 Ferulic acid
1 ferumoxytol
1 temozolomide
1 Radiotherapy/Radiation
1 verapamil
1 hydroxychloroquine
1 doxorubicin
1 Genistein (soy isoflavone)
1 Calorie Restriction Mimetics
1 Spermidine
1 Docosahexaenoic Acid
1 chitosan
1 Matrine
1 immunotherapy
1 methotrexate
1 Magnetic Field Rotating
1 Magnesium
1 magnetic nanoparticles
1 Naringin
1 Phenylbutyrate
1 borneol
1 Auranofin
1 Parthenolide
1 acetaminophen
1 Formononetin
1 acetazolamide
1 Shikonin
1 statins
1 triptolide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1849  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page